life short liver upiniti outperform
initi coverag enanta pharmaceut inc outperform
rate pt base view compani uniqu molecular
optim capabl proven mechan could translat superior
product profil grow field liver diseas competitor demonstr
approach licens product mavyret hepat hcv provid
fund via royalti compani lead pipelin asset develop
nonalcohol steatohepat nash primari biliari cholang pbc
initi trial indic believ moa rel de-risk
could becom potenti backbon therapi believ data
drive upsid rsv hbv earli stage program provid option
mavyret glecaprevir-pibrentasvir viekira paritaprevir-ritonavir-ombitasvir-
dasabuvir mavyret launch still growth phase
alreadi among top perform hcv estim hcv royalti
reach hcv royalti stream fulli support
develop enta on-going project
compani advanc clinic asset develop
nash pbc oral activ agonist farnesoid
 receptor fxr may higher potenc select compar
competitor recent enter trial nash pbc
view program partial de-risk molecul could
improv version compar fxr agonist alreadi use
pbc previous shown efficaci nash preclin studi
show higher potenc select translat lower pruritu without
ldl-c increas trial
number proof-of-concept readout nash pbc provid
signific catalyst next two year potenti unlock sharehold
valu pbc data potenti nash data progress
rsv hbv could also creat valu
see well posit deliv long-term growth differenti
nash invest vs competitor rel de-risk compar peer
aim improv upon proven fxr mechan superior product
profil non-dilut fund royalti stream support
oper posit near-term ep cash flow
compani use robust chemistry-
driven approach drug discoveri
capabl creat small molecul
diseas enanta research
current focus hepat viru
nash /pbc respiratori syncyti
analyst certif import disclosur see disclosur
infect
viral
assum hcv royalti fund on-going develop
pipelin asset potenti bd
assum hcv stabl
assum develop nash pbc
acceler enter market
estim pbc nash respect
greater expect sale mavyret
hvb rsv product enter progress
enta uniqu approach drug develop focus thorough
optim compound could provid competit advantag
nash pbc compani success demonstr hcv
mavyret expect continu perform mavyret hcv
deliv royalti fund develop new pipelin asset nash
pbc hbv rsv
preliminari data rsv
select hbv candid
nash pbc data
fail develop nash pbc
mavyret fail defend market share
price target base dcf valuat methodolog assum wacc residu growth rate
due patent expir model cash balanc million debt estim total peak hcv royalti
estim total peak nash sale un-risk-adjust risk-adjust
estim total peak pbc sale un-risk-adjust risk-adjust estim
complet septemb cash near-term clinic studi fund hcv royalti
key downsid risk price target clinic develop risk regulatori risk current phase trial addit risk come
lower expect peak sale market hcv drug due higher anticip competit failur gain support
medic commun healthcar prescrib third-parti payor risk relat partnership novarti legal challeng
patent protect product
initi coverag inc outperform rate
price target base view compani focu fundament
develop chemic optim lead compound could translat
competit advantag contend compet import area liver
viral diseas see well-posit deliv long-term growth
differenti nash invest peer de-risk compar peer
aim improv upon exist fxr mechan superior product profil
royalti stream support oper posit near-term ep
exhibit could deliv growth improv upon establish moa
royalti stream support oper
compani receiv royalti partner two success drug mavyret
glecaprevir-pibrentasvir viekira paritaprevir-ritonavir-ombitasvir-dasabuvir
hepat hcv mavyret recent launch still growth phase
alreadi among top perform hcv hcv royalti stream fulli support
develop enta on-going project compani lead clinic
asset develop nonalcohol steatohepat nash primari biliari
cholang pbc oral activ agonist farnesoid receptor fxr
play critic role bile acid synthesi carbohydr lipid metabol
regul insulin sensit growth regener liver injuri sever
fxr agonist develop potenti backbon therapi pbc nash
enta steroid non-carboxyl acid may higher potenc select
compar competitor recent enter trial nash pbc
also develop treatment respiratori syncyti viru rsv schedul begin
studi plan select clinic candid hepat hbv
estim total peak hcv royalti estim total peak
nash sale un-risk-adjust risk-adjust
estim total peak pbc sale un-risk-adjust risk-
adjust estim complet septemb
cash near-term develop fund hcv royalti
invest thesi enta uniqu approach drug develop focus
thorough optim compound could provid competit advantag nash
pbc compani success demonstr hcv mavyret expect
continu perform mavyret hcv deliv royalti fund develop
new pipelin asset nash pbc hbv rsv
hcv drug mavyret provid sever advantag treatment
believ royalti stream provid cash fund develop
pipelin potenti busi develop could acceler growth
view program partial de-risk molecul could
improv version fxr agonist alreadi use pbc
previous shown potenti efficaci nash
companytickermcrevenuesreturn assetsnash statuspotenti launchpositionmoaoth on-going molecul establish moafxr establish efficaci pbc biopsi efficaci nash pbc on-going cirrhosi marketfxr establish efficaci pbc biopsi efficaci nash pbc on-going posit biomark moathr first class nash fh initi mix dyslipidemia moappar first class nash pbc ongoingconsensu ep enanta pharmaceut inc
nash one enta mani competit advantag focu cirrhot
patient group sever patient studi fewer compani
increasingli crowd nash space potenti repres larg
opportun due higher diagnosi rate higher unmet medic need
number proof-of-concept readout nash pbc provid
signific catalyst next two year potenti unlock sharehold
valu view pbc data potenti nash data
progress rsv hbv could also creat valu
deliv posit clinic data see valu stock reach
price target offer substanti upsid potenti
price target base dcf valuat methodolog assum
wacc residu growth rate due patent expir model
cash balanc million debt
estim total peak hcv royalti estim total peak
nash sale un-risk-adjust risk-adjust
estim total peak pbc sale un-risk-adjust risk-
adjust estim complet septemb
cash near-term develop fund hcv royalti
key downsid risk price target clinic develop risk regulatori risk
current phase trial addit risk come lower expect
peak sale market hcv drug due higher anticip
competit failur gain support medic commun healthcar
prescrib third-parti payor risk relat partnership novarti
legal challeng patent protect product
exhibit catalyst calendar
time calendar fiscal asset dose-rang studi pbc intrepid earli dose-rang studi nash data rsv challeng hbv candid data pbc initi initi file file pbcsourc oppenheim co estim compani inform outperform
face sever major catalyst next month data becom
avail nash pbc program addit rsv trial could initi
could enter clinic hbv asset
histori stock price ownership
enta stock price ytd vs increas
increas nbi ownership predominantli hedg fund invest advisor
mutual fund insid own daili averag volum share
current short interest float day cover
stock price increas upon approv mavyret japan mileston
payment data intrepid pbc trial initi
present nash-tag confer fda track design grant
nash pbc gener upsid date data easl enta
hbv core inhibitor demonstr posit result along data nash
factset research note result view indic futur perform
inc watertown ma-bas biopharmaceut
compani focus develop therapi liver viral diseas includ
hcv hbv nash pbc rsv
success co-develop mavyret glecaprevir-pibrentasvir viekira
paritaprevir-ritonavir-ombitasvir-dasabuvir hepat hcv
market mavyret recent launch still growth phase
alreadi among top perform hcv stream cash fulli support
develop on-going project believ hcv close peak decreas
onward due price pressur fewer avail patient
compani lead clinic asset develop nonalcohol
steatohepat primari biliari cholang oral activ agonist
farnesoid receptor play critic role bile acid synthesi carbohydr
lipid metabol regul insulin sensit growth regener liver
injuri molecul fulli develop hold exclus world-wide right
file ip grant patent expir sever fxr agonist
develop potenti backbon therapi pbc nash enta edp-
steroid non-carboxyl acid may higher potenc select compar
competitor recent enter trial nash pbc also
develop asset treatment respiratori syncyti viru rsv schedul
initi compani plan select candid hbv
estim total peak hcv royalti estim total peak
nash sale un-risk-adjust risk-adjust
estim total peak pbc sale un-risk-adjust risk-
adjust estim complet septemb
cash near-term develop fund hcv royalti
complet cash fund hcv royalti use
 potenti bd
exhibit sale estim segment
exhibit contd sale estim segment
hepat viral diseas liver hepat hepat begin acut
infect peopl viru remain bodi result chronic diseas
long-term liver problem vaccin prevent hepat
hepat hcv typic contract contact blood bodi
fluid anoth individu infect hcv peopl acut
hepat symptom hcv detect via blood test first test
test hcv antibodi
patient hcv infect us treat
diagnos varieti antivir agent achiev viral clearanc accord
cdc survey us preval hcv total
case acut hepat report cdc estim actual
number infect almost accord gilead
diagnos patient treat nearli
patient experi chronic symptom chronic infect individu
develop liver cirrhosi period hcv cirrhosi becom
common indic liver transplant us account
case svr may achiev patient
antivir use hcv infect start show reduct liver transplant need
cirrhot hcv patient retrospect studi eu cirrhot patient
receiv antivir therapi show week treat patient
inactiv soon week start therapi patient
delist transplant list belli et al eventu
patient delist
approxim peopl get hepat clear viru
exhibit approv hcv treatment enta mavyret viekira highlight blue
royalti partner
exhibit contd approv hcv treatment enta mavyret viekira highlight
blue royalti partner
term newer regimen gilead harvoni introduc follow abbv
viekira pak report world-wide sale five lead hcv therapi
total approxim billion cure rate increas close
increas competiton fewer patient intoduc zepatir
regimen introduc epclusa pan-genotyp regimen ww
sale seven lead hcv therapi declin
quarter end septemb abbv new pan-genotyp regimen mavyret
us maviret ex-u approv us eu japan jurisdict
includ approv treatment treatment-nav non-cirrhot hcv patient
also introduc new regimen vosevi approv
regimen includ approv specifi daa-experienc patient
hcv drug direct act antivir daa includ one combin two
inhibitor proteas protein polymeras
interfer replic viru host cell
collabor develop paritaprevir one
three daa regimen market viekira pak paritaprevir-ritonavir-
ombitasvir-dasabuvir introduc non-cirrhot patient
earli stage compens cirrhosi combin contain
paritaprevir viekirax use genotyp hcv patient
develop second proteas inhibitor glecaprevir combin abbv
second inhibitor pibrentasvir coformul market mavyret
maviret ex-u mavyret approv pan-genotyp fixed-dos
combin treatment dose once-daili three oral tablet taken food chronic
hcv patient without cirrhosi new treatment mavyret also use certain
harder treat subpopul includ patient cure prior treatment
either proteas inhibitor inhibitor sever chronic kidney diseas ckd
genotyp chronic hcv
mavyret climb market share posit us reach strong posit
major countri japan germani spain itali follow result
increas global hcv sale guidanc guid hcv revenu
abbv hcv revenu mavyret us
hcv revenu ex-u revenu receiv
royalti
believ competiton continu caus price pressur hcv market
expect mavyret maintain current leadership posit market share
decreas thereaft see overal hcv patient number decreas
receiv annual tier royalti proteas product develop
agreement rang low doubl digit blend basi
low doubl digit high teen base abbv calendar year net sale
hcv regimen alloc proteas product regimen
term amend agreement net sale mavyret/maviret
regimen contain glecaprevir alloc glecaprevir net sale purpos
calcul royalti wherea net sale regimen contain
paritaprevir net sale regimen contain paritaprevir alloc
paritaprevir net sale
nonalcohol fatti liver diseas nafld nonalcohol steatohepat nash
caus liver diseas countri nafld condit defin
excess fat accumul form triglycerid steatosi liver
hepatocyt histolog subgroup nafld patient liver cell injuri
inflamm addit excess fat steatohepat type nafl spectrum
condit design nash nash dramat increas risk cirrhosi liver
failur hepatocellular carcinoma nash wide consid liver
express metabol syndromediseas relat diabet mellitu type insulin
cholesterol hypertriglyceridemia hypertens exact progress diseas
understood especi multifactori caus accord two-
hit hypothesi first hit involv accumul tg hepatocyt caus
viciou cycl metabol dysfunct presenc hepat steatosi
establish progress steatohepat involv second hit oxid stress
exhibit progress nafld/nash
three underli activ use measur nash activ liver steatosi
inflamm hepatocyt balloon total na score repres sum score
steatosi lobular inflamm balloon rang accord
na prerequisit nash steatosi balloon discrimin factor
current approv endpoint nash fibrosi improv nash resolut
measur biopsi
exhibit score nash along clinic endpoint
patient typic asymptomat earli stage nafld diseas
suspect patient show elev level enzym alanine-transaminas alt
aspart transaminas ast non-invas techniqu mri
ultrasound ct use confirm steatosi transient elastographi fibroscan
detect fibrosi assess liver stiff gold standard way clinic
verifi nash liver biopsi key aim field develop non-invas test
nash nafld allow screen
exhibit diagnosi nash
standard care nash lifestyl chang better manag relat
metabol diseas diabet hyperlipidemia possibl bariatr surgeri
pharmacolog treatment exist nash creat larg opportun base
need
exhibit clinic endpoint nash
approxim million individu us estim progress nash
nash-rel cirrhosi model nash patient us
receiv treatment use younossi et al hepatolog templat
calcul proport nash patient fall categori nash without
fibrosi nash fibrosi nash compens cirrhosi nash
decompens cirrhosi nash portal hypertens
exhibit annual predict case nafld subcategori studi estim
nash patient fibrosi fb patient nash compens cirrhosi cc
us alon
opportun nash later market
potenti superior molecul
develop oral small molecul fxr agonist nash pbc
trial healthi volunt nafld patient show safeti improv
lipid target engag recent initi trial could proof-
of-concept top-lin data week treatment
investig nash compound target sever aspect multifactori diseas
fibrosi lipid inflamm insulin signal compound directli target lipid
synthesi fxr nv ppar gnftf thr-b
ligand thr rational correct lipid
homeostasi target metabol storag triglycerid
inflammatori lipid speci reduc nash
exhibit categori moa nash
farnesoid receptor fxr transcript factor regul cholesterol alpha-
hydroxylas bile acid natur ligand fxr fxr play critic role bile
acid synthesi carbohydr lipid metabol regul insulin sensit
growth regener liver injuri bile acid circul liver
intestin back cycl call enterohepat circul fxr highli
express tissu particip bile acid metabol liver intestin
kidney high dietari cholesterol activ liver receptor shown
neg affect balanc storag oxid fatti acid
turn process non-triglycerid metabolit diacylglycerol
lysophosphatidyl cholin drive lipotox injuri liver cell one critic fxr target
gene gut fibroblast growth secret growth factor
signal cell-surfac receptor tyrosin kinas fxr shown
involv liver cirrhosi activ hepat stellat cell hsc thought
mediat process liver fibrosi secret extracellular matrix protein
ultim lead scar liver tissu fxr activ also reduc hepat
express sterol regulatori element bind protein result reduc triglycerid
cholesterol content liver fxr also play critic role insulin sensit fxr
activ lower plasma glucos free fatti acid triglycerid total cholesterol
addit direct role fxr indirectli regul carbohydr lipid metabol
insulin sensit increas secret small intestin
exhibit moa fxr pathway nash
three type nuclear receptor peroxisom proliferator-activ receptor ppar
identifi ppar ppar ppar ppar mainli influenc fatti acid
metabol activ lower lipid level ppar mostli involv
regul adipogenesi energi balanc lipid biosynthesi ppar
particip fatti acid oxid mostli skelet cardiac muscl also
regul blood glucos cholesterol level recogn ppar
group also modul inflammatori respons regul cell divis associ
liver fibrogenesi tumorigenesi categori includ thiazolidendion tzd
genfit elafibranor cymabay seladelpar
exhibit moa ppar pathway nash
anti-inflammatori compound aim reduc amount inflamm liver
liver natur regen abil compensatori growth howev sustain
sever liver injuri lead scenario gener apoptot cell
outpac bodi abil effect remov surround tissu
build-up apoptot materi lead cell death increas inflamm
disease-driven excess apoptosi result develop scar tissu fibrosi
lead tissu destruct eventu reduc capac organ
function normal conatu develop emricasan oral activ pan-caspas
proteas inhibitor design reduc activ human caspas enzym
mediat inflamm apoptosi allergan cenicriviroc cvc dual inhibitor
protein call play key role inflamm fibrosi
exhibit overview nash develop target fxr receptor
target separ moa thyroid hormon receptor normal
lipid synthesi thyroid hormonesthyroxin
regul cholesterol triglycerid fatti liver insulin sensit hormon
also regul bodi weight exert physiolog effect bind specif
nuclear receptor thyroid hormon receptor wide distribut
throughout bodi two isoform major isoform liver
kidney thyroid predominantli express brain adipos tissu
anterior pituitari gland specif target thr- rather thr- critic
avoid cardiac side effect major potenti differenti benefit thr- target
favor effect plasma cholesterol lipoprotein level multipl
mechan includ increas clearanc increas express
ldlr high-dens lipoprotein hdl uptak scaveng receptor
class type bile acid synthesi via
anoth thr- candid develop vike
thr- candid termin develop quatrx
karobio eprotirom due liver injuri ast alt level increas
significantli respect
companydrugmechanismstatusnashstatusdataintercept obetichol acid oca fxr regener fibrosi top-line earli revers cirrhosi initi bridg fibrosi compens stellar trial nash bridg fibrosi on-going stellar comp cirrhosi on-going top-line trial patient drug vs placebo achiev reduct fibrosi stage w/o worsen nash progress cirrhosi vs placebo progress cirrhosi vs placebo safeti genfit gnft elafibranor resolv trial on-going top-line novn tropifexor flight-fxr studi on-going enanta data safeti seladelparppar pbc onlyallegan former tobira cenicriviroc cvc immunomudul auror trial cur trial patient drug vs placebo achiv reduct fibrosi stage w/o worsen nash safeti galm glmd aramcholfatty-acid bile-acid nash ongoingfail meet endpoint hcv studi nafld top-lin ingelheimbi data expect -select top-line posit on-going complet april biopsysignific improv rel decreas liver fat mri patient treat compar placebo data mri surrogateth higher dose show statist signific reduct hepat steatosi non-invasive marker fibrosi vs placebo conatu cnat emricasancaspas cirrhosisposit data hcv nafld biomarkersvik vk -select data mild hypercholesterolemia outperform
exhibit mechan action thyroid hormon receptor target compound
differenti
fxr ligand well-establish class within nash research one
compound icpt oca sever compound tropifexor
could provid backbon therapi icpt oca also approv pbc help
demonstr class molecul safe human
invest time resourc optim candid expertis
medicin chemistri believ fxr agonist steroid non-
carboxyl acid modifi addit non-steroid bind element could deliv
increas potenc higher select fxr vs receptor
exhibit product attribut differenti increas molecular
optim could translat increas potenc higher select
anim model shown increas efficaci vs oca term fibrosi
reduct bile duct ligat bdl rat
exhibit potenti increas potenc demonstr anim model vs oca
exhibit potenti increas potenc demonstr mcd-induc anim model vs
safeti pk biomark nafld
develop oral fxr agonist nash pbc trial
healthi volunt adult presumpt nafld present current
trial nash initi data expect
week treatment sever fxr also shown poc data nash
believ support develop indic
dose oral suspens daili trial patient
placebo patient overal mean nafld cohort sad
compon test mg patient mad compon dose
healthi nafld patient mg day
exhibit trial design healthi volunt nafld patient
strong fxr target engag demonstr dose mg
increas reduc subject pn subject even
sensit signific effect also observ paramet lowest multipl
dose mg pk profil support once-daili dose
healthi volunt nafld subject
exhibit chang lipid level trial healthi volunt hv
treatment-emerg advers event occur patient headach pruritu
placebo constip pruritu occurr mild
moder occur multipl dose mg case
subject discontinu treatment mad phase mg dose level one
transient grade alt/ast elev one moder pruritu
exhibit trial healthi volunt nafld patient
accord safeti toler pk proof target engag support
progress once-daili dose data present nash-tag
confer jan easl
clinic develop nash pbc
on-going trial random double-blind placebo-control trial
involv subject biopsy-proven nash fibrosi fibrosi stage
phenotyp diagnosi nash base elev alt diagnosi type diabet
subject random receiv either one two dose match
placebo week
primari endpoint studi chang baselin alt level week
safeti although list clinicaltri gov studi also focu evalu
multipl secondari endpoint play signific role nash includ imag
non-invasive marker fibrosi steatosi result expect
also develop patient primari biliari cirrhosi pbc rare
liver diseas primarili affect adult women begin middl age mark
autoimmune-medi damag bile duct circul bile acid liver
time destruct bile duct caus bile acid accumul toxic level
liver lead progress degrad chronic inflamm obstruct
normal bile flow also known medic term cholestasi damag healthi
liver bile key compon hepat gi system serv help digest fat
fat-solubl vitamin small intestin degre sever somewhat
heterogen time pbc eventu lead liver failur death notabl
recent emerg obesity-rel diseas nash non-alcohol
steatohepat pbc frequent caus liver transplant us
new patient pbc typic present one two way complaint frequent
pruritu itch tingl fatigu via find elev alp routin
blood test pbc design orphan diseas us europ discuss
detail make highli accur determin diseas
preval difficult intercept estim approxim person
pbc develop countri roughli diagnos
treat urso analysi us market size suggest total
popul diagnos treat pbc patient approxim
approxim patient non-respond urso otherwis elig
second-lin therapi oca drug
fxr target bile acid analog oca recent approv base singl
studi primari composit endpoint defin respond rate compris
percentag patient alp time upper limit normal uln decreas
alp least total bilirubin less equal upper limit normal
cbay seladelpar pursu ident indic differ moa gild
fxr also develop pbc
pbc
initi trial pbc end intrepid trial
week random double-blind placebo-control studi evalu safeti
toler pharmacokinet efficaci subject pbc
without inadequ respons urso efficaci assess
evalu reduct level alkalin phosphatas alp vs placebo data could
avail result compet trial urso inadequ set
list
exhibit result competitor pbc
cbayincyseladelpar ursodiolocaliva /- ursodiolmechn actionppar delta agonistfxr post ursodiol post ursodiol failureadministrationor twice dailyor mg daili titrationcomosit endpoint respond rate decreas score alp less uln decreas alp least total bilirubin less equal vs vs placeboa vs vs respond rate compris percentag patient alp time upper limit normal uln decreas alp least total bilirubin less equal upper limit normal enanta pharmaceut inc
hbv rsv
develop candid hbv rsv current model due
earli stage develop
hepat viru hbv infect liver life-threaten treat
estim approxim million peopl world-wide chronic infect
patient chronic hbv infect develop chronic liver diseas
includ cirrhosi liver cancer liver decompens estim total number
peopl chronic infect hbv world-wide around million current
approach treatment includ interferon therapi and/or inhibitor hbv revers
transcriptas treatment interferon offer modest cure rate accompani
seriou side effect includ flu-lik symptom fatigu headach nausea revers
transcriptas inhibitor effect suppress viru often requir
lifelong therapi rare result full erad viru liver
focus new core inhibitor impact capsid assembl interfer
viral process approach support core inhibitor novira
janssen demonstr clinic reduct viral dna chronic
hbv patient short-term phase clinic studi
preclin data present intern liver congress
pari april data demonstr chimer scid mous model
human liver cell reduc viral dna rna level hbv log
baselin four week treatment demonstr favor toler
pharmacokinet profil plan advanc multipl new core inhibitor
preclin test announc first hbv candid later
respiratori syncyti viru rsv infect lung common caus
bronchiol pneumonia children year age unit state
year children age group hospit due rsv infect
current safe effect treatment avail treat rsv infect
focus n-protein mechan target replic process rsv
identifi clinic candid potent inhibitor rsv-a rsv-
 initi clinic studi end calendar effect
antivir medic prescrib rsv gener low true cure rate
expect top-lin data phase studi later begin phase
proof-of-concept challeng studi rsv-infect human end calendar
hcv model constant market share mavyret viekira
model declin addit also model declin patient y/i
y/i beyond assum increas gross-to-net
adjust offset potenti net price increas lead constant net price
time model hcv sale mavyret
viekira estim total peak hcv royalti
estim least nash patient unit state
preval model nash without fibrosi nash
fibrosi nash compens cirrhosi nash
decompens cirrhosi base research approxim nash fibrosi
patient cirrhot nash patient popul typic studi
fxr diagnosi undergo form treatment project
potenti approv model initi net price
annual us half three-fourth us price eu japan
respect base drug use larg popul model
potenti penetr nash patient nash patient
expect peak sale reach nash fibrosi un-risk-adjust us
row assum probabl success model risk-
adjust peak revenu nash
pbc set model case us case eu assum
fail urso elig treatment model potenti
penetr us eu assum chronic use
estim net treatment cost launch rapidli decreas edp-
use nash forecast un-risk-adjust peak sale pbc
us row assum probabl success peak risk-adjust
sale us row
exhibit project revenu hcv/nash/pbc un-risk-adjust adjust
nash pbc probabl success
exhibit project revenu hcv/nash/pbc un-risk adjust adjust
nash pbc probabl success
expect licens composit matter patent paritaprevir expir
unit state without extens co-own patent pend patent
applic cover compani particular solid form dosag method
manufactur use glecaprevir treat variou indic expect expir
model loss ip patent includ composit matter
pend model expir well beyond
jay luli ph presid chief execut offic director
dr luli join enanta juli prior join enanta dr luli entrepreneur
resid oxford bioscienc partner join oxford march dr luli
held posit senior vice presid research develop oper
senior vice presid discoveri strategi oper millennium pharmaceut
follow millennium merger leukosit inc serv senior vice
presid drug discoveri preclin develop prior join leukosit
held number senior drug discoveri posit
dr luli receiv univers illinoi urbana/champaign
ph synthet organ chemistri univers california berkeley
yat sun ph senior vice presid research develop chief
dr join enanta novemb prior join enanta dr held key
leadership posit receiv two
chairman award outstand research led discoveri
develop numer immunosuppress antibacteri drug prior abbott
dr member cardiovascular drug discoveri team schering-plough dr
receiv ph organ chemistri univers chicago complet
postdoctor fellowship ohio state univers indiana univers
paul mellett senior vice presid financ administr chief
mr mellett join enanta septemb april august
held posit senior vice presid chief offic essenti
therapeut previous mr mellett cfo vice presid administr
inc publicli held biotechnolog compani acquir
genzym corpor decemb mr mellett serv
cfo marshal contractor construct manag firm special
pharmaceut biotechnolog semiconductor industri acquir
mr mellett employ deloitt
touch llp public account firm promot audit partner mr
mellett receiv busi administr boston colleg
nathali adda senior vice presid chief medic offic
dr adda join enanta june dr adda specialist infecti diseas
year experi pharmaceut industri phase
global clinic research develop commerci recent dr adda
chief medic offic vice-president clinic develop medic regulatori affair
transgen sa led oncolog infecti diseas program sinc
senior medic director medic lead incivek
telaprevir clinic program design
phase phase program led medic team success market
applic registr us canada asia earlier career held
medic research posit gilead boehring
ingelheim work program infecti diseas human
immunodefici viru hepat viru hepat viru
dr adda graduat univers pari receiv doctor
medicin well master degre biostatist post-gradu
work infecti diseas
dr ocain join enanta sinc dr ocain independ
biotechnolog consult provid consult servic varieti compani
member execut team senior vice presid
research develop compani focus
neurodevelopment disord previous work millennium pharmaceut
held posit increas respons drug discoveri program
manag mostli recent held posit vice presid inflamm
discoveri work procept inc held senior-level drug
discoveri posit addit respons busi develop activ prior
procept serv medicin chemistri depart wyeth-ayerst research
dr ocain receiv biolog scienc univers
wisconsin-eau clair ph pharmaceut chemistri univers
wisconsin-madison complet post-doctor fellowship chemistri
univers minnesota
nathaniel gardin senior vice presid gener counsel
mr gardin join enanta previous corpor secur law
partner privat practic year start palmer dodg llp continu
merger edward angel palmer dodg llp becam
edward wildman palmer llp sinc mr gardin co-chair firm
life scienc group co-chair busi law depart
privat practic mr gardin enanta outsid counsel secretari sinc
found led ipo legal team also serv year truste joslin
diabet center inc boston member execut committe
chair compens committe mr gardin receiv
harvard colleg univers virginia school law
model hcv sale mavyret viekira
estim total peak hcv royalti
model initi net price annual us
us price eu japan respect base drug use
larg popul model potenti penetr nash patient
nash patient expect peak sale reach nash fibrosi un-
risk-adjust us row assum probabl success
model risk-adjust peak revenu nash assum
probabl success nash forecast un-risk-adjust peak sale pbc
us row assum probabl success peak risk-
adjust sale us row project potenti
approv nash pbc
exhibit probability-adjust sale forecast
exhibit sale forecast
risk un-adjust revenu sale sale royaltiesof salesblend mavyret royalti viekira royalti hcv nash nash pbc pbc adjust revenu adjustmentsprob hcvprobabl nash hcv nash nash pbc pbc year enanta pharmaceut inc
valu per share dcf assum wacc residu
growth rate ep estim
respect expect growth ep
well financ cash balanc well substanti hcv royalti
exhibit dcf valuat
exhibit dcf sensit analysi around probabl success asset
yeartermin valu growth valu valu per sharetermin valu growth rate outperform
exhibit incom statement forecast
except per share data fy probabl adj product royalti revenu total goods- cogs- gross oper expensesresearch develop adjust research develop share-bas compens total share-bas gener administr adjust sell gener administr share-bas compens total share-bas share-bas compens exclud non- op other- total oper expens oper interest dividend interest incom incom comprehens incom loss comprehens incom incom tax expens tax basic share outstand share outstand ep ep
exhibit balanc sheet forecast
fy asset cash short-term market prepaid expens current account receiv incl unbil inventories- defer tax assets- total current long-term market properti equip defer tax non-curr asset restrict total liabilitiescurr liabil account accru expens current incom tax payable- total current long-term portion warrant seri nonconvert prefer long-term portion defer revenue- long-term debt- total total stockhold total liabil outperform
exhibit statement forecast
fy incom adjustmentsstock compens depreci amort defer incom premium market amort premium market chang fair valu warrant liabil seri nonconvert prefer loss sale assets- accru interest includ convert note payable- incl incom tax benefit exercis stock chang oper asset liabilitiesaccount receiv incl unbil inventories- prepaid expens current account payabl accru incom tax asset flow sale purchas avail sale purchas fix incl matur market flow proce issuanc common stock- incom tax benefit exercis stock proceed/pay exercis option proce issuanc convert notes- princip payment promissori note- incl payment capit leas flow effect fx- net increas decreas equival equival
discount analysi except per-shar data mn except per-shar data revenu growth chang work work capit valu growth valu stock oppenheim valu per sharetermin valu growth rateequ valu per shareprob success nashprob success pbc
risk un-adjust revenu sale sale royaltiesof salesblend mavyret royalti viekira royalti hcv nash nash pbc pbc adjust revenu adjustmentsprob hcvprobabl nash hcv nash nash pbc pbc oppenheim co estimatescalendar year enanta pharmaceut inc
nash
probabl success
pbc
probabl success
collabor revenu mileston
good
research develop
adjust research develop non-gaap
share-bas compens
total share-bas compens
sell gener administr
adjust sell gener administr non-gaap
share-bas compens sg
total share-bas compens
total share-bas compens exclud non-gaap op ex
interest dividend incom
stock price compani mention report
